We are contrasting Puma Biotechnology Inc. (NASDAQ:PBYI) and Sinovac Biotech Ltd. (NASDAQ:SVA) on their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology Inc.	201.52M	5.11	146.96M	-3.90	0.00
Sinovac Biotech Ltd.	229.93M	1.96	29.04M	0.50	14.62

Table 1 demonstrates Puma Biotechnology Inc. and Sinovac Biotech Ltd.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both companies.

	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology Inc.	-72.93%	-301.5%	-74.1%
Sinovac Biotech Ltd.	12.63%	20.7%	10.9%

Risk & Volatility

Puma Biotechnology Inc. has a -0.13 beta, while its volatility is 113.00% which is less volatile than S&P 500. Sinovac Biotech Ltd.’s 0.39 beta is the reason why it is 61.00% less volatile than S&P 500.

Liquidity

The Current Ratio of Puma Biotechnology Inc. is 3 while its Quick Ratio stands at 3. The Current Ratio of rival Sinovac Biotech Ltd. is 2.5 and its Quick Ratio is has 2.3. Puma Biotechnology Inc. is better equipped to clear short and long-term obligations than Sinovac Biotech Ltd.

Institutional and Insider Ownership

Roughly 95.8% of Puma Biotechnology Inc. shares are held by institutional investors while 39.1% of Sinovac Biotech Ltd. are owned by institutional investors. About 11.3% of Puma Biotechnology Inc.’s share are held by insiders. On the other hand, insiders held about 11.4% of Sinovac Biotech Ltd.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Puma Biotechnology Inc.	3.83%	4.59%	-49.57%	-50.45%	-77.02%	-75.59%
Sinovac Biotech Ltd.	-1.34%	-4.92%	3.97%	-13.55%	-4.8%	-6.85%

For the past year Sinovac Biotech Ltd. has weaker performance than Puma Biotechnology Inc.

Summary

Sinovac Biotech Ltd. beats on 9 of the 11 factors Puma Biotechnology Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; and Split viron pandemic influenza vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. In addition, it has completed pre-clinical studies for varicella, sabin inactivated polio, and hepatitis A and B vaccines; and focuses on commencing clinical trials for pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and rubella vaccine. The company has a collaboration agreement with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal conjugate vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.